Although advances have been made in the development of antiangiogenesis targeted therapy and surgery, metastatic clear cell renal cell carcinoma (ccRCC) is still incurable. Activation-induced cytidine deaminase (AID) is mainly expressed in a variety of germ and somatic cells, and induces somatic hypermutation and class-switch recombination, playing a vital role in antibody diversification. We confirmed that AID was expressed at a higher level in ccRCC tissues than in the corresponding nontumor renal tissues. We explored the impact of AID on ccRCC proliferation, invasion, and migration. In 769-p and 786-0 cells, expression of an AID-specific short hairpin RNA significantly reduced AID expression, which markedly inhibited tumor cell invasion, proliferation, and migration. Previous studies showed that AID is associated with Wnt ligand secretion mediator (WLS/GPR177), cyclin-dependent kinase 4 (CDK4), and stromal cell-derived factor-1 (SDF-1/CXCL12) regulation, which was further confirmed in human ccRCC tissues. Therefore, we studied the relationship between AID and these three molecules, and the impact of AID on epithelial-to-mesenchymal transition in ccRCC. WLS/GPR177, SDF-1/CXCL12, and CDK4 were sensitive to 5-azacytidine (a DNA demethylation agent), which reverted the inhibition of carcinogenesis caused by AID repression. In summary, AID is an oncogene that might induce tumorigenesis through DNA demethylation. Targeting AID may represent a novel therapeutic approach to treat metastatic ccRCC.
Get full access to this article
View all access options for this article.
References
1.
AndersenA., and JonesD.A. (2013). APC and DNA demethylation in cell fate specification and intestinal cancer. Adv Exp Med Biol, 754, 167–177.
2.
ArakiA., JinL., NaraH., TakedaY., NemotoN., GaziM.Y., et al. (2019). IL-21 enhances the development of colitis-associated colon cancer: possible involvement of activation-induced cytidine deaminase expression. J Immunol, 202, 3326–3333.
3.
BhutaniN., BradyJ.J., DamianM., SaccoA., CorbelS.Y., and BlauH.M. (2010). Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature, 463, 1042–1047.
4.
BhutaniN., BurnsD.M., and BlauH.M. (2011). DNA demethylation dynamics. Cell, 146, 866–872.
5.
BouyssouJ.M., GhobrialI.M., and RoccaroA.M. (2016). Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett, 380, 315–318.
ConticelloS.G. (2008). The AID/APOBEC family of nucleic acid mutators. Genome Biol, 9, 229.
8.
CortellinoS., XuJ., SannaiM., MooreR., CarettiE., CiglianoA., et al. (2011). Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell, 146, 67–79.
9.
DuanZ., ZhengH., LiuH., LiM., TangM., WengX., et al. (2016). AID expression increased by TNF-alpha is associated with class switch recombination of Igalpha gene in cancers. Cell Mol Immunol, 13, 484–491.
10.
FuJ., JiangM., MirandoA.J., YuH.M., and HsuW. (2009). Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. Proc Natl Acad Sci USA, 106, 18598–18603.
11.
GhidiniM., PetrelliF., GhidiniA., TomaselloG., HahneJ.C., PassalacquaR., et al. (2017). Clinical development of mTOR inhibitors for renal cancer. Expert Opin Investig Drugs, 26, 1229–1237.
12.
HamaidiI., CoquardC., DanilinS., DormoyV., BeraudC., RothhutS., et al. (2019). The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma. Oncogene, 38, 60–72.
13.
HashamM.G., DonghiaN.M., CoffeyE., MaynardJ., SnowK.J., AmesJ., et al. (2010). Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat Immunol, 11, 820–826.
14.
HaslerJ., RadaC., and NeubergerM.S. (2011). Cytoplasmic activation-induced cytidine deaminase (AID) exists in stoichiometric complex with translation elongation factor 1alpha (eEF1A). Proc Natl Acad Sci USA, 108, 18366–18371.
15.
HseuY.C., ThiyagarajanV., TsouH.T., LinK.Y., ChenH.J., LinC.M., et al. (2016). In vitro and in vivo anti-tumor activity of CoQ0 against melanoma cells: inhibition of metastasis and induction of cell-cycle arrest and apoptosis through modulation of Wnt/beta-catenin signaling pathways. Oncotarget, 7, 22409–22426.
16.
HuT.H., YaoY., YuS., HanL.L., WangW.J., GuoH., et al. (2014). SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Cancer Lett, 354, 417–426.
17.
LiG., PoneE.J., TranD.C., PatelP.J., DaoL., XuZ., et al. (2012). Iron inhibits activation-induced cytidine deaminase enzymatic activity and modulates immunoglobulin class switch DNA recombination. J Biol Chem, 287, 21520–21529.
18.
LiH., LiQ., MaZ., ZhouZ., FanJ., JinY., et al. (2019). AID modulates carcinogenesis network via DNA demethylation in bladder urothelial cell carcinoma. Cell Death Dis 10,251.
19.
LiuN., YangC., BaiW., WangZ., WangX., JohnsonM., et al. (2019). CADM2 inhibits human glioma proliferation, migration and invasion. Oncol Rep, 41, 2273–2280.
20.
LjungbergB., AlbigesL., Abu-GhanemY., BensalahK., DabestaniS., Fernandez-PelloS., et al. (2019). European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol, 75, 799–810.
21.
MacDonaldB.T., TamaiK., and HeX. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 17, 9–26.
22.
MartinA., BardwellP.D., WooC.J., FanM., ShulmanM.J., and ScharffM.D. (2002). Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature, 415, 802–806.
23.
MatsumotoY., MarusawaH., KinoshitaK., NiwaY., SakaiY., and ChibaT. (2010). Up-regulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer. Gastroenterology, 139, 1984–1994.
24.
MohriT., NagataK., KuwamotoS., MatsushitaM., SugiharaH., KatoM., et al. (2017). Aberrant expression of AID and AID activators of NF-kappaB and PAX5 is irrelevant to EBV-associated gastric cancers, but is associated with carcinogenesis in certain EBV-non-associated gastric cancers. Oncol Lett, 13, 4133–4140.
25.
Montamat-SicotteD., LitzlerL.C., AbreuC., SafaviS., ZahnA., OrthweinA., et al. (2015). HSP90 inhibitors decrease AID levels and activity in mice and in human cells. Eur J Immunol, 45, 2365–2376.
26.
MorganH.D., DeanW., CokerH.A., ReikW., and Petersen-MahrtS.K. (2004). Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. J Biol Chem, 279, 52353–52360.
27.
MotzerR.J. (2016). Perspective: what next for treatment?. Nature, 537, S111.
28.
MunozD.P., LeeE.L., TakayamaS., CoppeJ.P., HeoS.J., BoffelliD., et al. (2013). Activation-induced cytidine deaminase (AID) is necessary for the epithelial-mesenchymal transition in mammary epithelial cells. Proc Natl Acad Sci USA, 110, E2977–E2986.
29.
NishigakiM., AoyagiK., DanjohI., FukayaM., YanagiharaK., SakamotoH., et al. (2005). Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res, 65, 2115–2124.
30.
OkazakiI.M., HiaiH., KakazuN., YamadaS., MuramatsuM., KinoshitaK., et al. (2003). Constitutive expression of AID leads to tumorigenesis. J Exp Med, 197, 1173–1181.
31.
PoneE.J., ZhangJ., MaiT., WhiteC.A., LiG., SakakuraJ.K., et al. (2012). BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-kappaB pathway. Nat Commun, 3, 767.
32.
QiJ., YuY., Akilli OzturkO., HollandJ.D., BesserD., FritzmannJ., et al. (2016). New Wnt/beta-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals. Gut, 65, 1690–1701.
33.
RaiK., HugginsI.J., JamesS.R., KarpfA.R., JonesD.A., and CairnsB.R. (2008). DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell, 135, 1201–1212.
34.
RobbianiD.F., BothmerA., CallenE., Reina-San-MartinB., DorsettY., DifilippantonioS., et al. (2008). AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell, 135, 1028–1038.
35.
RobbianiD.F., BuntingS., FeldhahnN., BothmerA., CampsJ., DeroubaixS., et al. (2009). AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell, 36, 631–641.
36.
SchmidS.C., SatheA., GuerthF., SeitzA.K., HeckM.M., MaurerT., et al. (2017). Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin. Urol Oncol, 35, 544.e1–544.e10.
37.
SeoJ., KeeH.J., ChoiH.J., LeeJ.E., ParkS.Y., LeeS.H., et al. (2018). Inhibition of Wntless/GPR177 suppresses gastric tumorigenesis. BMB Rep, 51, 255–260.
38.
SharpeK., StewartG.D., MackayA., Van NesteC., RofeC., BerneyD., et al. (2013). The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res, 19, 6924–6934.
39.
ShenH.M., BozekG., PinkertC.A., McBrideK., WangL., KenterA., et al. (2008). Expression of AID transgene is regulated in activated B cells but not in resting B cells and kidney. Mol Immunol, 45, 1883–1892.
40.
SherrC.J., BeachD., and ShapiroG.I. (2016). Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov, 6, 353–367.
41.
SinghM., YelleN., VenugopalC., and SinghS.K. (2018). EMT: mechanisms and therapeutic implications. Pharmacol Ther, 182, 80–94.
42.
SongL., GuoL., and LiZ. (2017). Molecular mechanisms of 3,3'4,4',5-pentachlorobiphenyl-induced epithelial-mesenchymal transition in human hepatocellular carcinoma cells. Toxicol Appl Pharmacol, 322, 75–88.
43.
StaszewskiO., BakerR.E., UcherA.J., MartierR., StavnezerJ., and GuikemaJ.E. (2011). Activation-induced cytidine deaminase induces reproducible DNA breaks at many non-Ig Loci in activated B cells. Mol Cell, 41, 232–242.
44.
StavnezerJ. (2011). Complex regulation and function of activation-induced cytidine deaminase. Trends Immunol, 32, 194–201.
45.
StoneL. (2015). Kidney cancer: AXL RTK—a therapeutic target in RCC?. Nat Rev Urol, 12, 475.
46.
WrightR.L., SlemmonsK.K., and VaughanA.T. (2015). Estradiol induces gene proximity and MLL-MLLT3 fusion in an activation-induced cytidine deaminase-mediated pathway. Leuk Lymphoma, 56, 1460–1465.
47.
XieY., ZhongL., DuanD., and LiT. (2019). Casticin inhibits invasion and proliferation via downregulation of beta-catenin and reversion of EMT in oral squamous cell carcinoma. J Oral Pathol Med, 48, 897–905.
48.
XuH., JiangW., ZhuF., ZhuC., WeiJ., and WangJ. (2016). Expression of Wntless in colorectal carcinomas is associated with invasion, metastasis, and poor survival. APMIS, 124, 522–528.
49.
XuZ., ZanH., PoneE.J., MaiT., and CasaliP. (2012). Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat Rev Immunol, 12, 517–531.
50.
YangP.T., AnastasJ.N., ToroniR.A., ShinoharaM.M., GoodsonJ.M., BosserhoffA.K., et al. (2012). WLS inhibits melanoma cell proliferation through the beta-catenin signalling pathway and induces spontaneous metastasis. EMBO Mol Med, 4, 1294–1307.
51.
YangX.Z., ChengT.T., HeQ.J., LeiZ.Y., ChiJ., TangZ., et al. (2018). LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/beta-catenin pathway. Mol Cancer, 17, 126.
52.
YounA., KimK.I., RabadanR., TyckoB., ShenY., and WangS. (2018). A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes. BMC Med Genomics, 11, 98.
53.
ZanH., and CasaliP. (2013). Regulation of Aicda expression and AID activity. Autoimmunity, 46, 83–101.
54.
ZarnegarB., HeJ.Q., OganesyanG., HoffmannA., BaltimoreD., and ChengG. (2004). Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci USA, 101, 8108–8113.
55.
ZhangF., MaX., LiH., ZhangY., LiX., ChenL., et al. (2018). FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma. Int J Cancer, 142, 2543–2557.
56.
ZhangJ.X., MaiS.J., HuangX.X., WangF.W., LiaoY.J., LinM.C., et al. (2014). MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of beta-catenin signaling. Ann Oncol, 25, 2196–2204.
57.
ZhouX., LiangZ., LiK., FangW., TianY., LuoX., et al. (2019). Exploring the natural piericidins as anti-renal cell carcinoma agents targeting peroxiredoxin 1. J Med Chem, 62, 7058–7069.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
